Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Neuroendocrine tumor cell proliferation inhibited by novel interferon-lambda
July 14th, 2006
According to recently published research from Germany, a novel interferon-lambda s induces antiproliferative effects in neuroendocrine tumor cells. "Interferon-alpha (IFN-alpha) is used for biotherapy of neuroendocrine carcinomas. The interferon-lambda s (IL-28A/B and IL-29) are a novel group of interferons," wrote K. Zitzmann and colleagues, University of Munich. "In this study, we investigated the effects of the IFN-lambda s IL-28A and IL-29 on human neuroendocrine BON1 tumor cells. Similar to IFN-alpha, incubation of BON1 cells with IL-28A (10 ng/ml) and IL-29 (10 ng/ml) induced phosphorylation of STAT1, STAT2, and STAT3, significantly decreased...
Source: Genomics & Genetics Weekly (2006-07-14)
|
